A Phase 2 Placebocontrolled Randomized Proof of Concept Study of A Respiratory Syncytial Virus RSV Vaccine in Pregnant Women
Research payments
$11,614,695
Through program year 2020, $11,614,695 in research payments was reported against A Phase 2 Placebocontrolled Randomized Proof of Concept Study of A Respiratory Syncytial Virus RSV Vaccine in Pregnant Women, across 983 payments, paid by Pfizer Inc..
- Paid by
- Pfizer Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2020 | Research | $6,376,388 | 682 |
| 2019 | Research | $5,238,308 | 301 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Cynthia Robbins Fort Worth, TX Named on 32 payments
- Paul Matherne Biloxi, MS Named on 31 payments
- Robert Jeanfreau Metairie, LA Named on 29 payments
- Vicki Miller Houston, TX Named on 29 payments
- Jeffrey Baker Idaho Falls, ID Named on 29 payments
- Charles Plimpton Phoenix, AZ Named on 28 payments
- Keith Vrbicky Norfolk, NE Named on 28 payments
- John Wideman Cullman, AL Named on 27 payments
- Peyman Banooni Beverly Hills, CA Named on 27 payments
- Samuel Campbell North Chesterfield, VA Named on 27 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.